According to CNBC’s premarket movers report, AstraZeneca shares rose 3% after its experimental COPD drug, tozorakimab, meaningfully reduced flare-ups in two late-stage trials. The company said full results will be presented at an upcoming medical meeting.
Tripadvisor gained 3% after Bank of America upgraded the stock to Buy from Neutral, citing accelerating activist engagement and rising strategic optionality across the portfolio. Argan rose more than 10.5% following a fourth-quarter earnings and revenue beat, with earnings of $3.47 per share on revenue of $262.1 million; analysts polled by FactSet had expected $1.98 per share on revenue of $255.3 million. Unity Software surged more than 11% after issuing preliminary first-quarter adjusted EBITDA of $130 million to $135 million, higher than prior guidance of $105 million to $110 million. Newsmax shares moved about 5% higher after quarterly revenue of $52.2 million exceeded the $44.0 million consensus estimate, and it forecast full-year revenue of $212 million to $216 million, above the Street estimate of $206.1 million.
Crypto stocks traded lower as Bitcoin slid another 3% on Friday, bringing two-day losses to more than 6%. Strategy, a cryptocurrency treasury company, fell more than 2%. Robinhood and Coinbase declined over 2.5% and 3%, respectively, in broader crypto-related trading.
Memory stocks also retreated, with Micron down 2% after a recent slide, SanDisk off more than 3%, and Western Digital and Lam Research down 2.3% and 1.5% respectively, in sympathy with the memory sector’s softer tone.
Energy shares rose as oil prices climbed again, lifting the sector. EOG Resources, Phillips 66, Diamond Energy and Devon Energy were each up more than 1%, contributing to the energy group among the S&P 500’s gainers.
Key takeaways
- AstraZeneca up 3% on late-stage COPD drug data; catalyst: two Phase III trials showing reduced flare-ups; implication: potential momentum for the COPD franchise ahead of further disclosures at an upcoming medical meeting.
- Unity Software up more than 11% after preliminary first-quarter adjusted EBITDA guidance of $130–$135 million, above prior guidance; implication: improved near-term profitability trajectory for its game-development platform.
- Argan up more than 10.5% on stronger-than-expected Q4 earnings and revenue; consensus had projected $1.98 per share on $255.3 million, while actual was $3.47 on $262.1 million; implication: stronger earnings delivery could lift investor confidence in its construction segment exposure.
- Tripadvisor up ~3% on upgrade to Buy from Neutral; catalyst: activist engagement and rising strategic optionality; implication: sentiment shift could attract additional investor attention.
- Newsmax about 5% higher after Q4 revenue beat and full-year guidance above expectations; implication: improved visibility for the conservative-leaning network’s growth trajectory.
What drove the move
The day’s biggest individual movers centered on company-specific catalysts rather than broad market shifts. AstraZeneca’s stock reaction followed news that tozorakimab delivered meaningful reductions in COPD flare-ups in two late-stage trials, with full results due to be shared at a forthcoming medical meeting. While the timing and details of the medical conference were not disclosed in the report, investors are likely parsing the potential longer-term implications for AstraZeneca’s respiratory portfolio and pipeline credibility.
Tripadvisor’s upgrade reflects rising activist engagement and a belief that the company’s portfolio offers greater strategic optionality than previously recognized. The upgrade suggests a potential re-rating of the travel platform as investors weigh multiple levers—pricing power, monetization opportunities, and possible strategic moves among holdings.
Argan’s strong fourth-quarter print underscored resilience in its construction and EPC (engineering, procurement, and construction) operations, with actual earnings well above consensus expectations. Unity’s guidance upgrade indicates improved early-year profitability momentum for its software platform serving game developers, implying a healthier near-term demand environment or stricter cost discipline in the first quarter.
Newsmax’s revenue beat and stronger-than-expected full-year guidance point to improving top-line momentum for a conservative-leaning media network, signaling potential for renewed advertiser interest or audience engagement that supports its growth trajectory.
Market reaction
Beyond single-name moves, the broader market narrative remained nuanced. The upbeat signals from the software and media names contrast with weakness in crypto-related stocks and memory names, illustrating a bifurcated mood among investors. The crypto complex has faced renewed pressure alongside bitcoin’s back-to-back declines, highlighting a renewed risk-off impulse that tends to hit high-beta areas and richly valued tech plays. In contrast, energy equities found support on higher oil prices, a familiar driver of capex optimism and earnings potential for energy producers.
What analysts are saying
In Argan’s case, analysts tracked by FactSet had forecast earnings of $1.98 per share on revenue of $255.3 million for the fourth quarter; the company reported $3.47 on $262.1 million in revenue, setting a clear beat against estimates. Newsmax’s quarterly revenue of $52.2 million exceeded the $44.0 million consensus, and its full-year revenue forecast of $212–$216 million topped the $206.1 million expectation, signaling room for upside in its revenue trajectory. Tripadvisor’s upgrade to Buy from Neutral by Bank of America points to a shift in sentiment tied to activist momentum and strategic optionality, though the research note did not provide a quantitative price target in the summarized report. For Unity, the revised EBITDA outlook exceeds prior guidance, suggesting a more favorable profitability trajectory though the company did not publish a comparable consensus figure in the report. AstraZeneca’s update did not include a parallel consensus read, and analysts may await more granular data at the medical meeting.
Bigger picture
Trading dynamics in this snapshot underscore how micro catalysts can drive distinct stock moves even as macro drivers tug markets in different directions. The energy complex’s strength aligns with a broader commodity-linked tilt that often cushions energy equities against rate volatility and inflation surprises. Conversely, the crypto and memory segments illustrate ongoing sensitivity to risk appetite and cyclical demand, with several names trading in lockstep with sector sentiment rather than fundamentals alone.
Investors will be watching near-term events for additional clarity. AstraZeneca’s full COPD data presentation at the upcoming medical meeting will be closely analyzed for any nuances that could influence near-term sentiment around its respiratory portfolio. Unity’s ongoing earnings cadence and any incremental detail on its profitability trajectory will be scrutinized by investors focused on cash-flow generation in software platforms. For Newsmax, the trajectory of advertising demand and audience engagement will inform whether the revenue path can sustain its guidance. Energy traders will remain focused on oil price movements, as crude trends continue to shape earnings expectations for the sector.
Looking ahead, the market will also digest broader macro cues, including central-bank communications and upcoming data releases that could sharpen the backdrop for risk assets. Investors should monitor how these drivers evolve as the quarter progresses, keeping an eye on the medical conference disclosures from AstraZeneca, and any additional guidance or results from Unity and Newsmax that could reinforce the current price actions.
